On October 22, 2020 Exelixis, Inc. (Nasdaq: EXEL) reported that its third quarter 2020 financial results will be released on Thursday, November 5, 2020 after the markets close (Press release, Exelixis, OCT 22, 2020, View Source [SID1234568869]). At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6945239 to join by phone.

A telephone replay will be available until 8:00 p.m. EST on November 7, 2020. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6945239. A webcast replay will also be archived on www.exelixis.com for one year.

On October 22, 2020 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results (Press release, ImmunoGen, OCT 22, 2020, View Source [SID1234568868]). Management will also provide a brief update on the business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

To access the live call by phone, dial (877) 621-5803; the conference ID is 9864218. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

On October 22, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 (Press release, Personalis, OCT 22, 2020, View Source [SID1234568867]). In conjunction with the release, the Company will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 9697771. The live webinar of the call may be accessed by visiting the Events section of the company’s website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company’s website.

On October 22, 2020 RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, reported that eight clinical abstracts evaluating the use of its novel technology were accepted for presentation during the virtual American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting, Oct. 24-28 (Press release, RefleXion Medical, OCT 22, 2020, View Source [SID1234568866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to have eight abstracts from leading academic clinicians highlighting our technology," said Sean Shirvani, M.D., senior vice president of Clinical and Medical Affairs at RefleXion. "The presentations will share new data on the potential of BgRT for targeting tumors in diverse anatomic locations and from varied histologies, including non-small cell lung, prostate and pancreatic cancers. The investigations also explore the exciting opportunity of leveraging PET information as a future biomarker with BgRT.

"Through our clinical partnerships, we continue to produce comprehensive, evidence-based research that builds on the strong foundation of previously published studies," continued Shirvani. "We believe the RefleXion X1 can form the backbone of any radiotherapy clinic, as it delivers IMRT/SBRT/SRS and unlocks opportunities for procedural growth with BgRT in local and metastatic disease."

The following presentations taking place during ASTRO 2020 evaluate RefleXion’s novel technology:

Sunday, Oct 25, 2:15 PM. Poster Session 02, Poster Hall:

2686 "Simultaneous Integrated Boost of Lung Tumors in the Stereotactic Ablative Setting using BgRT Tracked Delivery"
2831 "Use of a Detailed Process Map for Clinical Workflow of a New Biology-guided Radiotherapy (BgRT) Machine"
2768 "Feasibility of Biology-Guided Radiotherapy for Pancreatic Tumors: An Assessment of Normalized Target SUV"
Monday, Oct 26, 12:20 PM Physics 06 – Imaging and Response Assessment:

SS 21 – "Increased 18F-FDG Metabolic Activity During Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs"
Tuesday, Oct 27:

3:15 PM QP-19 – Physics – Motion Management "Feasibility of Biology-guided Radiotherapy (BgRT) Targeting FDG Avid Liver Metastases"
2:00 PM 2268 PV 06 Poster "FDG-PET Metrics in Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis"
2:00 PM 2258 PV 06 Poster "Prognostic Value of FDG-PET Metrics for Advanced NSCLC Patients Treated with First-line Immunotherapy"

On October 22, 2020 The Mary Kay Foundation℠ recently reported that awarded $1 million in grants to ten researchers on the frontline battling cancers that primarily affect women (Press release, The Mary Kay Foundation, OCT 22, 2020, View Source [SID1234568865]). The grants, which benefit institutions in Mary Kay’s home state of Texas all the way to Wisconsin and New York, are part of The Mary Kay Foundation’s annual cancer research grant cycle, totaling nearly $24 million since inception.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

After reviewing more than 75 applications, The Mary Kay Foundation Research Review Committee awarded $100,000 grants to 10 accredited cancer research institutions. This year’s grant recipients include:

Beckman Research Institute of City of Hope
Columbia University Irving Medical Center
NYU Grossman School of Medicine
Stanford University School of Medicine
The University of Texas Health Science Center at San Antonio
University of California San Diego
UT Southwestern Medical Center
The University of Tennessee Health Science Center
University of Virginia
University of Wisconsin School of Medicine and Public Health
"The Mary Kay Foundation has a two-fold mission: to end gender-based violence and empower researchers to find cures for cancers that primarily affect women," said Michael Lunceford, President of The Mary Kay Foundation Board of Directors. "Over the past several decades, our research grants have enabled some of the country’s top medical minds to make breakthroughs in treatments that we’re so proud of. Our hope—and belief—is that this year’s grantees will continue that inspiring research trend."

That research includes innovative studies from scientists like Dr. Hua Yu, Associate Chair and Professor in the Department of Immuno-Oncology at the Beckman Research Institute of City of Hope. Dr. Yu will use the grant provided by The Mary Kay Foundation to study the opposing roles of PARP and PARG inhibitors in regulating ovarian cancer immune responses. Dr. Paul Lambert, Howard M. Temin Professor and Chair of Oncology at the University of Wisconsin Schools of Medicine and Public Health, will use the funds to research the role of human’s microbiome in cervical cancer. In New York, Dr. Alberto Ciccia, Assistant Professor of Genetics & Development at Columbia University Medical Center, will use the funds to study large-scale functional analysis of BRCA1/2 single nucleotide variants.

"By offering continued support for these scientists and institutions," added Lunceford, "we are continuing Mary Kay’s ultimate goal, which is to better the lives of women everywhere."